F. Hoffmann-La Roche AG
Compare market positioning with top industry peers
Explore F. Hoffmann-La Roche
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$77.19B
Market Cap
$215.0B
Employees
101,000
Roche is functioning as the undisputed pioneer of personalized medicine, extracting revenues from its integrated pharmaceutical and diagnostics divisions that create uniquely powerful synergies in oncology and rare disease. Under CEO Thomas Schinecker, the Swiss healthcare giant generated exactly $62.7 billion in revenue and maintains a $215.0 billion market cap with exactly 101000 employees. The financial narrative in 2026 is entirely defined by post-biosimilar recovery; absorbing catastrophic biosimilar erosion of its legendary oncology blockbusters (Herceptin, Avastin, Rituxan), Roche extracts improving profitability by furiously advancing its differentiated next-generation immunology and obesity pipeline to replace lost revenues.
Revenue Trend Analysis
YoY Change
+1.6%
2-Year CAGR
+0.8%
Peak Year
2025
Trend
Consistent Growth
F. Hoffmann-La Roche AG has reported revenue across 3 fiscal years, compounding at +0.8% annually over 2 years. The most recent year saw a 1.6% increase versus the prior year. Revenue peaked in 2025 at $77.2B. Out of 2 reported periods, 2 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | YoY Change |
|---|---|---|
| FY2025 | $77.2B | +1.6% |
| FY2024 | $75.9B | +0.1% |
| FY2023 | $75.9B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
F. Hoffmann-La Roche AG reported approximately $62.7B in fiscal year 2025 with a team of 101,000 employees worldwide.
F. Hoffmann-La Roche AG strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Pharmaceuticals and Diagnostics is driven by steady cash generation and pricing power, enabling F. Hoffmann-La Roche AG to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "F. Hoffmann-La Roche AG Revenue & Financials." CorpDigest, https://corpdigest.com/company/roche/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>F. Hoffmann-La Roche AG reported $77B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/roche/financials" target="_blank" rel="noopener">CorpDigest — F. Hoffmann-La Roche AG financials</a></div>